Skip to Content

Notice

National Institute of Allergy and Infectious Diseases; Notice of Closed Meetings

Document Details

Information about this document as published in the Federal Register.

Document Statistics
Document page views are updated periodically throughout the day and are cumulative counts for this document including its time on Public Inspection. Counts are subject to sampling, reprocessing and revision (up or down) throughout the day.
Published Document

This document has been published in the Federal Register. Use the PDF linked in the document sidebar for the official electronic format.

Start Preamble

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meetings.

The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel HHS-NIH-CDC-SBIR 2018-1 Phase II Topic 053: Effective Targeted Delivery of RNA-based Vaccines and Therapeutics.

Date: April 15, 2020.

Time: 2:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate contract proposals.

Place: National Institute of Allergy and Infectious Diseases, National Institutes of Start Printed Page 15483Health, 5601 Fishers Lane, Room 3G22, Rockville, MD 20892 (Telephone Conference Call).

Contact Person: Inka I Sastalla, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G22, Rockville, MD 20852, (301) 761-6431, inka.sastalla@nih.gov.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; HHS-NIH-CDC SBIR PHS 2018-1 Phase II Topic 052: High-Throughput Assay Platform for Quantifying Latent HIV Reservoirs.

Date: April 21, 2020.

Time: 2:00 p.m. to 5:00 p.m.

Agenda: To review and evaluate contract proposals.

Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G22, Rockville, MD 20892 (Telephone Conference Call).

Contact Person: Inka I Sastalla, Ph.D., Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Room 3G22, Rockville, MD 20852, (301) 761-6431, inka.sastalla@nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Start Signature

Dated: March 13, 2020.

Miguelina Perez,

Program Analyst, Office of Federal Advisory Committee Policy.

End Signature End Preamble

[FR Doc. 2020-05630 Filed 3-17-20; 8:45 am]

BILLING CODE 4140-01-P